Munich, Germany, 21st March 2019 (fcf) – FCF Fox Corporate Finance strengthens its Life Science Advisory Board with the appointment of Dr. Alexandra Goll and Prof. Dr. Horst Domdey
FCF Fox Corporate Finance (“FCF”) is pleased to announce the appointment of two further renowned
experts to its Life Science Advisory Board. From now on, Dr. Alexandra Goll and Prof. Dr. Horst Domdey
will support and advise the financing specialist as part of the Life Science advisory board.
Dr. Alexandra Goll is an industry specialist with extensive experience across the entire value chain of
biopharmaceutical research, development and investment. Dr. Goll is managing director of BioPharma
Advisory, a strategy advisory firm specialized on innovative companies in Biotechnology, Med-Tech and
Pharma. Her experiences range from acting as Global Business Leader for HIV and CMV at HoffmannLa Roche to serving as General Partner at TVM Capital GmbH. With TVM, Dr. Goll was involved in
fundraising activities for TVM Capital GmbH and TVM Life Sciences and was, among others, an early
investor in Actelion Pharmaceuticals Ltd. and Pharmasset, Inc.. Alexandra was elected into the top 40
of most successful private equity females in Europe by Private Equity News in 2008. Commenting on
the announcement, Dr. Goll stated, “It is a pleasure to join the FCF Life Science Advisory Board,
complementing and supporting the life science activities of FCF. I am looking forward to contributing my
industry know-how to FCF.”
Since more than 20 years, Prof. Dr. Horst Domdey is the key person of the business-oriented life science
activities in the greater Munich area. As Managing Director of BioM Biotech Cluster Development GmbH
he oversees all ongoing local and regional activities in biotech, med-tech and health-tech. His excellent
network with hundreds of local and international scientists enables him to identify upcoming innovations
very early. He is the first contact for life science entrepreneurs who intend to start their own company
and he has accompanied in this role more than 100 start-ups in their realisation process. More than 40
of those received a seed investment through BioM AG, BioM’s finance arm. He has extensive knowledge
of company start-ups, financing and corporate support in all drug and technology development stages.
From 2010 to 2015, he supervised the 100 million Euro “m4 – Personalised Medicine” excellence cluster
programme, which involved more than 100 biotechnology companies and research institutes. Before
joining BioM, he held a professorship in biochemistry at the Gene Centre of the LMU Munich. „I am very
honoured to join FCF’s Life Science Advisory Board and am thrilled to build on previous successes”,
said Prof. Domdey.
Dr. Mathias Schott, Director of Life Sciences at FCF, is very excited about the new members: “With Dr.
Goll and Prof. Dr. Domdey, our board now has two further significant specialists with whom we can
further broaden the high level of expertise that we already have in the sophisticated field of life science.”
Arno Fuchs, CEO of FCF, also sees the latest additions to the Life Science Advisory Board as part of
his company’s overall strategy: “FCF operates as a financing specialist in segments that are challenging
not only in the area of finance, but also at the operating level. With this in mind, we always strive to
combine the highest available expertise in these areas within our committee members. The fact that we
can welcome Dr. Goll and Prof. Dr. Domdey to the Life Science Advisory Board, clearly shows how
consistent we are in implementing this strategy,” said Arno Fuchs.
With these appointments, FCF further complements its existing Life Science Advisory Board consisting
of Claus Schalper, Serial Entrepreneur with seed to IPO experience, and Dr. Holger Bengs, initiator and
organizer of European Chemistry Partnering, the latest conference / initiative for venture and growth
companies in the chemical space in Europe.
